GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: CDP-7657 | CDP7657 | DZP
Compound class:
Antibody
Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.
|
| No information available. |
Summary of Clinical Use  |
| Dapirolizumab pegol (CDP7657) has progressed to Phase 3 evaluation for SLE. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04294667 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 Interventional | UCB Pharma | ||
| NCT01093911 | Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | Phase 1 Interventional | UCB Pharma | 2 | |
